Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. He has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has an enviable track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products. Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, which he helped secure he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that secured at the time the single largest product licensing deal by an Australian biotech company, when Acrux licensed its testosterone product, Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.

 Hugh is an accomplished pharmaceutical and biotechnology executive with 20 years of experience in international business development, partnering, drug development and leadership of scientific teams. He has demonstrated commercial management skills, profit accountability, and senior oversight of drug development programs for the international market. Hugh has an enviable track record of being part of two significant exit transactions for the Australian life sciences industry, including two successful Phase 3 programs and two FDA approvals for Australian developed products. Hugh’s most recent role was the Chief Executive Officer of Hatchtech Pty Ltd, which he helped secure he helped secure a $200 million commercialisation agreement for its lead development product with global Indian pharmaceutical company Dr Reddy’s. In 2010, as Director of Business Development at Acrux Limited, Hugh was a key member of the team that secured at the time the single largest product licensing deal by an Australian biotech company, when Acrux licensed its testosterone product, Axiron™, to global pharmaceutical company Eli Lilly for up to US$335m in potential milestones plus royalties.